Oncotype DX®
The only test in the world that predicts
patient's response to chemotherapy
in early breast cancer
Teacher: Giorgos Kapetsis, Nikos Tsoulos
HerediGENE®
HerediGENE® is a diagnostic multi-gene test for hereditary cancer, which analyses 52 genes, including BRCA1 and BRCA2, which are involved in the increased risk of breast, ovarian, prostate, colorectal and other hereditary cancers.
Com.pl.i.t DX®
Personalised treatment based on tumour biology
For patients with lung, colorectal and breast cancer
Prime DX
Precision Individualized Medicine
For an effective personalised treatment plan for cancer
Avantect®
A pioneering test for the early detection and early diagnosis of pancreatic cancer
Signatera®
Molecular detection of minimal residual disease in blood